Erratum: Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid (Journal of Clinical Oncology (2016) 34 (2404-2415) DOI: 10.1200/JCO.2016.66.6487);Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid

Journal of Clinical Oncology

Volumn 34, Issue 20, 2016, Pages 2404-2415

  Pentsova, Elena I ^a   Shah, Ronak H ^a   Tang, Jiabin ^a   Boire, Adrienne ^a   You, Daoqi ^a   Briggs, Samuel ^a   Omuro, Antonio ^a   Lin, Xuling ^a   Fleisher, Martin ^a   Grommes, Christian ^a   Panageas, Katherine S ^a   Meng, Fanli ^a   Selcuklu, S Duygu ^a   Ogilvie, Shahiba ^a   Distefano, Natalie ^a   Shagabayeva, Larisa ^a   Rosenblum, Marc ^a   DeAngelis, Lisa M ^a   Viale, Agnes ^a   Mellinghoff, Ingo K ^a,b   Berger, Michael F ^a,c   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Medical Center   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BRAIN CANCER; BRAIN METASTASIS; CANCER PATIENT; CENTRAL NERVOUS SYSTEM CANCER; CEREBROSPINAL FLUID; FEMALE; GENE LOCUS; GENE MUTATION; GLIOMA; HIGH THROUGHPUT SEQUENCING; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; NEXT GENERATION SEQUENCING; PRIMARY TUMOR; PRIORITY JOURNAL; AGED; BRAIN TUMOR; CELL FREE SYSTEM; EVALUATION STUDY; GENETICS; MUTATION; PROCEDURES;

ADULT; AGED; BRAIN NEOPLASMS; CELL-FREE SYSTEM; DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION;

EID: 84977499654     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.73.8708     Document Type: Erratum

References (62)

1. Haber DA, Gray NS, Baselga J: The evolving war on cancer. Cell 145:19-24, 2011
2. Bettegowda C, Sausen M, Leary RJ, et al: Detection of circulating tumor DNA in early- and latestage human malignancies. Sci Transl Med 6: 224ra24, 2014
3. Rhodes CH, Honsinger C, Sorenson GD: PCRdetection of tumor-derived p53 DNA in cerebrospinal fluid. Am J Clin Pathol 103:404-408, 1995
4. Swinkels DW, de Kok JB, Hanselaar A, et al: Early detection of leptomeningeal metastasis by PCR examination of tumor-derived K-ras DNA in cerebrospinal fluid. Clin Chem 46:132-133, 2000
5. Shingyoji M, Kageyama H, Sakaida T, et al: Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol 6:1215-1220, 2011
6. Chen WW, Balaj L, Liau LM, et al: BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids 2: e109, 2013
7. Pan W, Gu W, Nagpal S, et al: Brain tumor mutations detected in cerebral spinal fluid. Clin Chem 61:514-522, 2015
8. Wang Y, Springer S, Zhang M, et al: Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A 112:9704-9709, 2015
9. De Mattos-Arruda L, Mayor R, Ng CK, et al: Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839, 2015
10. Cheng DT, Mitchell TN, Zehir A, et al: Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 17:251-264, 2015
11. DePristo MA, Banks E, Poplin R, et al: A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43:491-498, 2011
12. Mose LE, Wilkerson MD, Hayes DN, et al: ABRA: Improved coding indel detection via assembly-based realignment. Bioinformatics 30:2813-2815, 2014
13. Cibulskis K, Lawrence MS, Carter SL, et al: Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31:213-219, 2013
14. Ye K, Schulz MH, Long Q, et al: Pindel: A pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25:2865-2871, 2009
15. Wang K, Li M, Hakonarson H: ANNOVAR: Functional annotation of genetic variants from highthroughput sequencing data. Nucleic Acids Res 38: e164, 2010
16. Abecasis GR, Auton A, Brooks LD, et al: An integrated map of genetic variation from 1,092 human genomes. Nature 491:56-65, 2012
17. Exome Aggregation Consortium: About ExAC. http://exac.broadinstitute.org
18. Thorvaldsdóttir H, Robinson JT, Mesirov JP: Integrative Genomics Viewer (IGV): High-performance genomics data visualization and exploration. Brief Bioinform 14:178-192, 2013
19. Rausch T, Zichner T, Schlattl A, et al: DELLY: Structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28:i333-i339, 2012
20. Engelman JA, Mukohara T, Zejnullahu K, et al: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116:2695-2706, 2006
21. Yu HA, Arcila ME, Rekhtman N, et al: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19:2240-2247, 2013
22. Ayoola A, Barochia A, Belani K, et al: Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: An update. Cancer Invest 30:433-446, 2012
23. Camidge DR, Pao W, Sequist LV: Acquired resistance to TKIs in solid tumours: Learning from lung cancer. Nat Rev Clin Oncol 11:473-481, 2014
24. Paraiso KH, Xiang Y, Rebecca VW, et al: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:2750-2760, 2011
25. Shi H, Hugo W, Kong X, et al: Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4:80-93, 2014
26. Niessner H, Forschner A, Klumpp B, et al: Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med 2:76-85, 2013
27. Junttila TT, Akita RW, Parsons K, et al: Ligandindependent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440, 2009
28. Janiszewska M, Liu L, Almendro V, et al: In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet 47:1212-1219, 2015
29. Cerami E, Gao J, Dogrusoz U, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401-404, 2012
30. Zarghooni M, Bartels U, Lee E, et al: Wholegenome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 28: 1337-1344, 2010
31. Brat DJ, Verhaak RG, Aldape KD, et al: Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481-2498, 2015
32. Eckel-Passow JE, Lachance DH, Molinaro AM, et al: Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499-2508, 2015
33. Johnson BE, Mazor T, Hong C, et al: Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189-193, 2014
34. Diaz LA Jr, Bardelli A: Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 32: 579-586, 2014
35. Heitzer E, Ulz P, Geigl JB: Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 61: 112-123, 2015
36. Siravegna G, Mussolin B, Buscarino M, et al: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21: 827, 2015
37. Dawson SJ, Tsui DW, Murtaza M, et al: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199-1209, 2013
38. Murtaza M, Dawson SJ, Tsui DW, et al: Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497: 108-112, 2013
39. Romanel A, Gasi Tandefelt D, Conteduca V, et al: Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med 7:312re10, 2015
40. Oxnard GR, Paweletz CP, Kuang Y, et al: Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative nextgeneration genotyping of cell-free plasma DNA. Clin Cancer Res 20:1698-1705, 2014
41. Garcia-Murillas I, Schiavon G, Weigelt B, et al: Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 7: 302ra133, 2015
42. Spellman PT, Gray JW: Detecting cancer by monitoring circulating tumor DNA. Nat Med 20: 474-5, 2014
43. Diehl F, Schmidt K, Choti MA, et al: Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985-990, 2008
44. Mohan S, Heitzer E, Ulz P, et al: Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 10:e1004271, 2014
45. Azad AA, Volik SV, Wyatt AW, et al: Androgen Receptor gene aberrations in circulating cell-free DNA: Biomarkers of therapeutic resistance in castrationresistant prostate cancer. Clin Cancer Res 21: 2315-2324, 2015
46. Paweletz CP, Sacher AG, Raymond CK, et al: Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res 22:915-922, 2016
47. Kinde I, Wu J, Papadopoulos N, et al: Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 108:9530-9535, 2011
48. Kennedy SR, Schmitt MW, Fox EJ, et al: Detecting ultralow-frequency mutations by duplex sequencing. Nat Protoc 9:2586-2606, 2014
49. Clarke JL, Perez HR, Jacks LM, et al: Leptomeningeal metastases in the MRI era. Neurology 74:1449-1454, 2010
50. Weston CL, Glantz MJ, Connor JR: Detection of cancer cells in the cerebrospinal fluid: Current methods and future directions. Fluids Barriers CNS 8: 14, 2011
51. Brastianos PK, Carter SL, Santagata S, et al: Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5:1164-1177, 2015
52. Sawyers CL: Shifting paradigms: The seeds of oncogene addiction. Nat Med 15:1158-1161, 2009
53. Heon S, Yeap BY, Britt GJ, et al: Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 16:5873-5882, 2010
54. Toyokawa G, Seto T, Takenoyama M, et al: Insights into brain metastasis in patients with ALK+ lung cancer: Is the brain truly a sanctuary. Cancer Metastasis Rev 34:797-805, 2015
55. Teplinsky E, Esteva FJ: Systemic therapy for HER2-positive central nervous system disease: Where we are and where do we go from here. Curr Oncol Rep 17:46, 2015
56. Jackman DM, Holmes AJ, Lindeman N, et al: Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24: 4517-4520, 2006
57. Balak MN, Gong Y, Riely GJ, et al: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494-6501, 2006
58. Dhruva N, Socinski MA: Carcinomatous meningitis in non-small-cell lung cancer: Response to high-dose erlotinib. J Clin Oncol 27:e31-e32, 2009
59. Katayama T, Shimizu J, Suda K, et al: Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4: 1415-1419, 2009
60. Kawamura T, Hata A, Takeshita J, et al: High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFRTKIs. Cancer Chemother Pharmacol 75:1261-1266, 2015
61. Grommes C, Oxnard GR, Kris MG, et al: "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-oncol 13:1364-1369, 2011
62. Zagouri F, Sergentanis TN, Bartsch R, et al: Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: A systematic review and pooled analysis. Breast Cancer Res Treat 139:13-22, 2013